SG11201908909PA - Methods for the stimulation of dendritic cell (dc) precursor population "pre-dc" and their uses thereof - Google Patents
Methods for the stimulation of dendritic cell (dc) precursor population "pre-dc" and their uses thereofInfo
- Publication number
- SG11201908909PA SG11201908909PA SG11201908909PA SG11201908909PA SG 11201908909P A SG11201908909P A SG 11201908909PA SG 11201908909P A SG11201908909P A SG 11201908909PA SG 11201908909P A SG11201908909P A SG 11201908909PA
- Authority
- SG
- Singapore
- Prior art keywords
- singapore
- international
- subject
- immune
- pct
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 title abstract 7
- 239000002243 precursor Substances 0.000 title abstract 3
- 230000000638 stimulation Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 abstract 4
- 102220240796 rs553605556 Human genes 0.000 abstract 3
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 230000001613 neoplastic effect Effects 0.000 abstract 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 abstract 1
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201703628W | 2017-05-03 | ||
| PCT/SG2018/050219 WO2018203833A1 (fr) | 2017-05-03 | 2018-05-03 | Procédés de stimulation d'une population de précurseurs de cellules dendritiques (dc) « pré-dc » et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908909PA true SG11201908909PA (en) | 2019-10-30 |
Family
ID=64014506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908909P SG11201908909PA (en) | 2017-05-03 | 2018-05-03 | Methods for the stimulation of dendritic cell (dc) precursor population "pre-dc" and their uses thereof |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210100897A1 (fr) |
| EP (1) | EP3618860A4 (fr) |
| CN (1) | CN110869048A (fr) |
| SG (1) | SG11201908909PA (fr) |
| WO (1) | WO2018203833A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| EA008777B1 (ru) * | 2002-10-29 | 2007-08-31 | Коли Фармасьютикал Груп, Лтд. | Способы и продукты, относящиеся к лечению и предупреждению инфекции вируса гепатита c |
| WO2005023982A2 (fr) * | 2003-05-28 | 2005-03-17 | Univ. Of Louisville Research Foundation, Inc. | Procedes permettant d'ameliorer la prise de greffe de cellules souches hematopoietiques purifiees chez des receveurs allogeniques |
| JP4961556B2 (ja) * | 2004-12-09 | 2012-06-27 | 国立大学法人大阪大学 | ヘモゾイン誘導による自然免疫を利用したマラリア感染症の検出・測定、マラリア感染症の予防又は治療薬のスクリーニング、及び該自然免疫誘導の調節 |
| EP2548571A1 (fr) * | 2011-07-22 | 2013-01-23 | Institut Curie | Compositions dotées de supports de ciblage d'au moins un antigène sur des cellules dendritiques |
| WO2018035364A1 (fr) * | 2016-08-17 | 2018-02-22 | The Broad Institute Inc. | Produit et procédés utiles pour moduler et évaluer des réponses immunitaires |
-
2018
- 2018-05-03 EP EP18795003.5A patent/EP3618860A4/fr active Pending
- 2018-05-03 WO PCT/SG2018/050219 patent/WO2018203833A1/fr unknown
- 2018-05-03 SG SG11201908909P patent/SG11201908909PA/en unknown
- 2018-05-03 US US16/610,461 patent/US20210100897A1/en active Pending
- 2018-05-03 CN CN201880044972.7A patent/CN110869048A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018203833A1 (fr) | 2018-11-08 |
| EP3618860A4 (fr) | 2020-05-06 |
| US20210100897A1 (en) | 2021-04-08 |
| EP3618860A1 (fr) | 2020-03-11 |
| CN110869048A (zh) | 2020-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201804506RA (en) | Systems and methods for rendering multiple levels of detail | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201906235YA (en) | Narrowband time-division duplex frame structure for narrowband communications | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201806340YA (en) | Zika virus vaccine | |
| SG11201803711SA (en) | Hydrophilized polydiorganosiloxane vinylic crosslinkers and uses thereof | |
| SG11201804787UA (en) | Human immunodeficiency virus neutralizing antibodies | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
| SG11201804841VA (en) | Hardware integrity check | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201804916PA (en) | Three-dimensional polymer networks with channels situated therein | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201809561WA (en) | 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201907701YA (en) | Composition and method for preventing or delaying onset of myopia comprising atropine | |
| SG11201407801VA (en) | Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations | |
| SG11201901272WA (en) | Mesenchymal cell-derived exosomes to treat neurological disorders | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
| SG11201809865RA (en) | Break analysis apparatus and method |